Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis

Abstract

Background: Type 2 (T2) inflammation is implied in the pathogenesis of several coexisting diseases. Objectives: To estimate proportion of patients (pts) with moderate-to-severe (m/s) asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) or atopic dermatitis (AD) with comorbidities linked to T2 inflammation. Additionally, severity of T2 comorbidities in m/s asthma and m/s CRSwNP pts was estimated. Methods: A convenience sample of physicians from US and EU5 (France, Germany, Italy, Spain and the UK) were contacted (JAN2017–FEB2020) to identify and review medical records of pts with asthma, CRSwNP, or AD (all m/s disease). Based on physician judgement, comorbidities linked to T2 inflammation and severity of comorbidities were reported. Results: 761 physicians identified pts with m/s asthma (n=899), m/s CRSwNP (n=683), or m/s AD (n=367). In m/s asthma pts, 60%, 15%, 17% had allergic rhinitis (AR), AD, CRSwNP; in m/s CRSwNP pts, 46%, 53%, 9% had asthma, AR, AD; in m/s AD patients, 31%, 41%, and 3% had asthma, AR, CRSwNP. In m/s asthma and m/s CRSwNP pts, a high proportion of T2 comorbidities presented as m/s disease (Figure). Conclusions: High proportions of pts with m/s asthma, m/s AD, and m/s CRSwNP had comorbidities linked to T2 inflammation. Given the high comorbidity burden, an integrated treatment approach addressing underlying T2 inflammation should be considered.